drugset / Trial / NCT00813267

Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head

NCT00813267

Phase 0 Unknown 15 enrolled Jianming Tan
NaSingle-groupOpen-labelTreatment

Summary

Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs. The investigators will infuse expanded autologous MSCs and BMMNCs into patients with osteonecrosis of the femoral head. The study purpose is to examine whether this treatment will result in improvement in osteonecrosis of the femoral head.

Timeline

Start
2009-12
Primary completion
2011-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy Other
Subject bone marrow mononuclear cell Cell therapy Other

Indications